Table 2.
Clinical trials evaluating immune checkpoint inhibitors alone or in combination.
| NCT Number/Study Name | Targeting Agents | Comparison | Phase | Histology | Primary Endpoint | Therapy Setting | Status |
|---|---|---|---|---|---|---|---|
| NCT01668784/CheckMate 025 | nivolumab | everolimus | III | ccRCC | OS | at least second line | published |
| NCT02231749/CheckMate 214 | Nivolumab + ipilimumab | sunitinib | III | ccRCC | PFS, OS, ORR | first line | published |
| NCT03260894 | Pembrolizumab + epacadostat | sunitinib/pazopanib | III | ccRCC | ORR | first line | active not recruiting |
| NCT02853344/Keynote-427 | pembrolizumab | - | II | cc/nccRCC | ORR | all lines | active not recruiting |
| NCT02964078 | pembrolizumab+interleukin-2 | - | II | ccRCC | ORR | all lines | active not recruiting |
| NCT02960906/BIONIKK | nivolumab/ipilimumab/VEGFR-TKI | - | II | ccRCC | ORR | first line | recruiting |
| NCT03469713/NIVES | Nivolumab + SBRT | - | II | ccRCC | ORR | at least second line | recruiting |
| NCT02446860/ADAPTeR | nivolumab | - | II | ccRCC | Safety | pre and post-operative | recruiting |
| NCT02819596/Calypso | Durvalumab +/tremelimumab/savolitinib | - | II | cc/pRCC | DLT, OR | at least second line | recruiting |
| NCT03308396 | Durvalumab + guadecitabine | - | I/II | ccRCC | safe dose/ORR | at least second line | recruiting |
| NCT02989714 | Nivolumab + interleukin-2 | - | I/II | ccRCC | safety | third line | recruiting |
| NCT03024996/IMmotion010 | atezolizumab | placebo | III | ccRCC | DFS | adjuvant | recruiting |
| NCT03055013 | nivolumab | observation | III | ccRCC | DFS | adjuvant | recruiting |
| NCT03138512/CheckMate 914 | Nivolumab + ipilimumab | placebo | III | ccRCC | DFS | adjuvant | recruiting |
| NCT03142334/Keynote-564 | pembrolizumab | placebo | III | ccRCC | DFS | adjuvant | recruiting |
| NCT02575222 | nivolumab | - | I | ccRCC | safety | neo-adjuvant | active not recruiting |
| NCT03177239/ANZUP1602 | Nivolumab + ipilimumab | - | II | nccRCC | ORR | all lines | recruiting |
| NCT03075423/SUNIFORECAST | Nivolumab + ipilimumab | sunitinib | II | nccRCC | OS | first line | recruiting |
Abbreviations: ccRCC, clear cell renal cell carcinoma; nccRCC, non clear cell renal cell carcinoma; OS, overall survival; OR, overall response; PFS, progression-free survival; ORR, objective response rate; DLT, Dose-Limiting Toxicities; -, absence of comparison group.